Likvor 
Likvor AB
Likvor is a medical device company which has developed a system to be used in neurological investigations assessing cerebrospinal fluid (CSF) dynamics. The LIKVOR CELDA® SYSTEM is on the market today.
Product
Likvor’s core product, the CELDA® Instrument is a device to measure the dynamics of the cerebrospinal fluid (“CSF”) system. With increased understanding of the brain and neurological diseases, mapping CSF dynamics is becoming more and more important. CELDA® Instrument offers automatic and standardized protocols for multiple purposes in the diagnostic process – identifying patients suffering from normal pressure hydrocephalus (“NPH”) with dementia like symptoms, mapping CSF dynamics pre- and post-shunt surgery, shunt control, constant flow or constant pressure measurements, tap tests, bolus infusions etc. It is the first and only CE certified instrument in this field and will enable objective comparisons of research data from different clinics and research groups. With its flexibility and easy handling the CELDA® sets a new standard for investigations of CSF-dynamics. CELDA® Instrument is safer for the patient and yields a faster and more accurate diagnosis.
By using the LIKVOR CELDA® SYSTEM hospitals can make huge savings, in costs as they reduce the number of shunt reoperations, and in human suffering.
Likvor AB is marketing the LIKVOR CELDA® SYSTEM and LIKVOR CELDA® TOOLS. The system includes an instrument, a bed and a disposable tube set. The system is the result of over 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. The company has one patent in the US and two patents pending which includes both method and device.
Potential and the market
Statistics show that 1 in 10 dementia patients suffer from NPH. Studies indicate that approximately 1.4 million patients in Europe, USA and Japan suffer from NPH.
The CELDA® SYSTEM was CE certified in 2009, and currently there are 8 systems in clinical use with paying customers in Sweden, Denmark, Finland and the UK. To reach the European market, distributors will be used, two contracts are signed; for the German- and the UK-market. A potential clinical study in the US is being evaluated.
Next step
Likvor is looking for 20 MSK for the next three years. The capital will be used to speed up the market penetration in Europe and recruit sales personnel. Exit could be possible through an industrial buyout, for example from a shunt company.
